Perspective Therapeutics (CATX) Operating Income (2010 - 2026)

Perspective Therapeutics has disclosed Operating Income across 17 years of filings, most recently posting -$28.3 million for Q1 2026.

• Operating Income for Q1 2026 came in at -$28.3 million, down 29.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$120.0 million (down 20.36% YoY), and the FY2025 annual result was -$113.6 million, down 24.95% from the prior year.
• Operating Income came in at -$28.3 million for Q1 2026 at Perspective Therapeutics, up from -$39.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$1.4 million in Q1 2022 to a low of -$45.0 million in Q4 2024.
• The 5-year median for Operating Income is -$13.0 million (2024), against an average of -$16.9 million.
• Across the five-year window, Operating Income tumbled 609.38% in 2023 and rose 11.45% in 2025, its largest moves.
• Perspective Therapeutics' Operating Income stood at -$5.6 million in 2022, then plunged by 107.72% to -$11.7 million in 2023, then plunged by 285.27% to -$45.0 million in 2024, then grew by 11.45% to -$39.8 million in 2025, then rose by 29.0% to -$28.3 million in 2026.
• The last three Operating Income figures came in at -$28.3 million (Q1 2026), -$39.8 million (Q4 2025), and -$27.9 million (Q3 2025), per Business Quant data.